Analysis Tools
hematopoietic system
|
• at 20 weeks after pIpC induction, bones are pale, suggesting decreased erythropoiesis
• at 20 weeks after pIpC induction, erythroid TER-119+ cells are reduced in the bone marrow but a compensatory increase is seen in the spleen
|
|
• at 20 weeks after pIpC induction, myeloid cells are the predominant cell population in the bone marrow and are increased in the spleen
|
|
• at 20 weeks after pIpC induction, liver shows extramedullary hematopoiesis with highly atypical megakaryocytes, but islands with myelopoeisis and erythropoiesis can also be found
• at 20 weeks after pIpC induction, hematopoietic cells, including megakaryocytes are seen in the lung
• at 20 weeks after pIpC induction, colony assays of progenitors show extramedullary hematopoiesis with markedly increased erythroid and myeloid progenitor numbers in spleen
|
|
• at 20 weeks after pIpC induction, bone marrow shows hypercellularity with trilineage hyperplasia
|
|
• at 20 weeks after pIpC induction, an increase in numbers of megakaryocytes in the spleen and bone marrow is seen at 20 weeks of age, most with morphological abnormalities such as hyperchromatic, hyperlobulated nuclei, and bizarre nuclear configuration, and often forming clusters
|
|
• at 20 weeks after pIpC induction, colony assays of progenitors show extramedullary hematopoiesis with markedly increased erythroid and myeloid progenitor numbers in spleen
|
|
• at 20 weeks after pIpC induction, collagen-based culture indicates a massive expansion of CFU-MK in the spleen
|
|
• at 10 weeks after pIpC induction, mutants exhibit an increase in erythrocyte numbers
|
|
• at 10 weeks after pIpC induction, mutants exhibit elevated hemoglobin
|
|
• at 10 weeks after pIpC induction, mutants exhibit a slight decrease in mean corpuscular volume
|
|
• at 10 weeks after pIpC induction, mutants exhibit neutrophilia
|
|
• at 10 weeks after pIpC induction, mutants exhibit thrombocytosis
|
|
• at 20 weeks after pIpC induction, the relative amount of B and T cells in the spleen and bone marrow is reduced
|
|
• at 20 weeks after pIpC induction, the relative amount of B and T cells in the spleen and bone marrow is reduced
|
|
• at 20 weeks after pIpC induction, destruction of normal splenic architecture by atypical hematopoiesis is seen in some sections of the spleen
|
|
• splenomegaly is seen after pIpC induction
|
|
• spleen fibrosis is seen at 20 weeks after pIpC induction
|
immune system
|
• at 20 weeks after pIpC induction, myeloid cells are the predominant cell population in the bone marrow and are increased in the spleen
|
|
• at 10 weeks after pIpC induction, mutants exhibit neutrophilia
|
|
• at 20 weeks after pIpC induction, the relative amount of B and T cells in the spleen and bone marrow is reduced
|
|
• at 20 weeks after pIpC induction, the relative amount of B and T cells in the spleen and bone marrow is reduced
|
|
• at 20 weeks after pIpC induction, destruction of normal splenic architecture by atypical hematopoiesis is seen in some sections of the spleen
|
|
• splenomegaly is seen after pIpC induction
|
|
• spleen fibrosis is seen at 20 weeks after pIpC induction
|
skeleton
|
• bone marrow fibrosis is seen at 20 weeks after pIpC induction
|
growth/size/body
|
• splenomegaly is seen after pIpC induction
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| polycythemia vera | DOID:8997 |
OMIM:263300 |
J:134364 | |
